F-Prime-backed start­up hopes to lever­age AI and a su­per­com­put­er to emerge in pro­tein mis­fold­ing field

As star­tups con­tin­ue to delve in­to the pro­tein mis­fold­ing space, and net blue-chip VCs like the Or­biMed-backed Con­gru­ence ear­li­er this year, one start­up is look­ing to use a su­per­com­put­er, AI and a for­mer physi­cist to forge its path with­in the field.

Lon­don-based Pep­tone se­cured a $40 mil­lion Se­ries A round Thurs­day, co-led by F-Prime, to de­vel­op in­trin­si­cal­ly dis­or­dered pro­teins (IDPs) in­to po­ten­tial drugs for a range of dis­eases, in­clud­ing in­flam­ma­tion, can­cer and di­a­betes. The com­pa­ny is head­ed by Kamil Tami­o­la, a for­mer physi­cist who has a back­ground in NMR spec­troscopy and has worked with IDPs dur­ing his ca­reer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER